European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS
No Result
View All Result
European Business
No Result
View All Result
Home < INDUSTRIES Health

Roche’s Tecentriq approved by European Commission as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer

by Marie Weil
May 6, 2021
A A
Share on LinkedinShare on Twitter
  • Tecentriq significantly improved overall survival in people with high PD-L1 expression, compared with chemotherapy in a Phase III study
  • Tecentriq approval offers an alternative to chemotherapy for all eligible patients
  • This approval marks Tecentriq’s fourth indication in metastatic non-small cell lung cancer and fifth indication in lung cancer overall in the EU

Basel, 5 May 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq® (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression*, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.

“We are delighted to bring Tecentriq to people in the EU with this specific type of lung cancer,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “Tecentriq monotherapy has been shown to improve overall survival in people with high PD-L1 expression, when compared to chemotherapy, and therefore represents a new treatment option for people living with this difficult-to-treat disease.”

Tecentriq is now the first and only single-agent cancer immunotherapy with three dosing options, allowing administration every two, three or four weeks, giving physicians and patients greater flexibility on how they manage their treatment.

This approval is based on data from the Phase III IMpower110 study, which showed that Tecentriq monotherapy improved overall survival (OS) by 7.1 months compared with chemotherapy (median OS=20.2 versus 13.1 months; hazard ratio [HR]=0.59, 95% CI: 0.40–0.89; p=0.0106) in people with high PD-L1 expression (TC3 or IC3-wild-type [WT]).1 Safety for Tecentriq was consistent with its known safety profile, with no new safety signals identified. Grade 3–4 treatment-related adverse events were reported in 12.9% of people receiving Tecentriq, compared with 44.1% of people receiving chemotherapy.2

Tecentriq has shown clinically meaningful benefit in various types of lung cancer, with five currently approved indications in markets around the world. In Europe, Tecentriq now has four approved indications in NSCLC, including as a single agent or in combination with targeted therapies and/or chemotherapies. It was also the first approved cancer immunotherapy for the first-line treatment of adults with extensive-stage small cell lung cancer (SCLC) in combination with carboplatin and etoposide (chemotherapy).

Roche has an extensive development programme for Tecentriq, including multiple ongoing and planned Phase III studies across different settings in lung, genitourinary, skin, breast, gastrointestinal, gynaecological, and head and neck cancers. This includes studies evaluating Tecentriq both alone and in combination with other medicines, as well as studies in metastatic, adjuvant and neoadjuvant settings across various tumour types.

Tags: < Market

Related Industries

Health

Boehringer Ingelheim and Microsoft partner to drive patient-centric and AI-backed clinical development

October 23, 2026
Health

AstraZeneca announces new strategic collaboration with insitro to use advanced AI systems to develop transformative therapeutics for difficult to treat cardiometabolic diseases

October 16, 2026
Health

Boehringer Ingelheim investments into sustainability-related programs and health partnerships to reach EUR 500 million

September 30, 2026
Health

Philips-led projects win ITEA awards for advancing AI-enabled healthcare innovation

September 17, 2026
Health

Sanofi and Cheplapharm to create new strategic partnership in mature medicines

September 15, 2026
Health

Exor and Philips Extend Long-term Relationship Agreement

August 11, 2026

IHG Hotels & Resorts strengthens development focus in Greece & Cyprus with the appointment of Rozenn Lavaur Fournier as Director of Development

November 6, 2026

...

ABN AMRO and Rabobank complete transfer of Alfam

November 3, 2026

...

Alstom launches solar park in Matranovak site to reduce industrial carbon footprint in Hungary

October 21, 2026

...

Hilton and Scandic Sign New Nordics Strategic Agreement

October 20, 2026

...

Hyundai Motor Company Italy: Francesco Colonnese appointed President and CEO

November 7, 2026

...

AkzoNobel and Axalta to be called Axanzo following merger

October 16, 2026

...

Volvo Cars and NVIDIA expand partnership to advance safe automated driving

October 16, 2026

...

Siemens partners with NVIDIA to advance AI-driven, autonomous factories

October 20, 2026

...

Deutsche Bank and DWS extend strategic partnerships with Zurich until 2042

October 27, 2026

...

IBM and Siemens Collaborate on Research to Advance Nanostack Architecture

October 15, 2026

...

European Business European Business European Business

EUROPEAN BUSINESS is a premier source of corporate news, business information and insights across broad spectrum of industries in Europe and worldwide.  We are one of the members of the Business World Network.

RESOURCES

  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

CONTACT US

EDITORIAL:     editor # european-biz.com

PARTNERSHIP:     partnership # european-biz.com

HUMAN RESOURCE:     hr # european-biz.com

* (replace # with @)

  • Official Site

Copyright © EUROPEAN-BIZ.COM All rights reserved.

No Result
View All Result
  • HOME
  • SUSTAINABILITY
  • INVEST
  • MARKET
  • PARTNERSHIP
  • INNOVATION
  • PEOPLE
  • INSIGHTS

Copyright © EUROPEAN-BIZ.COM All rights reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist